These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 25288723)

  • 1. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.
    Kiiski JI; Pelttari LM; Khan S; Freysteinsdottir ES; Reynisdottir I; Hart SN; Shimelis H; Vilske S; Kallioniemi A; Schleutker J; Leminen A; Bützow R; Blomqvist C; Barkardottir RB; Couch FJ; Aittomäki K; Nevanlinna H
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):15172-7. PubMed ID: 25288723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
    Kiiski JI; Tervasmäki A; Pelttari LM; Khan S; Mantere T; Pylkäs K; Mannermaa A; Tengström M; Kvist A; Borg Å; Kosma VM; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Winqvist R; Nevanlinna H
    Breast Cancer Res Treat; 2017 Nov; 166(1):217-226. PubMed ID: 28702895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
    Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Shehzad U; Khan FA; Loya A; Hamann U
    Fam Cancer; 2023 Jan; 22(1):31-41. PubMed ID: 35802266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy.
    Silvestri V; Rizzolo P; Zelli V; Valentini V; Zanna I; Bianchi S; Tibiletti MG; Varesco L; Russo A; Tommasi S; Coppa A; Capalbo C; Calistri D; Viel A; Cortesi L; Manoukian S; Bonanni B; Montagna M; Palli D; Radice P; Peterlongo P; Ottini L
    Breast; 2018 Apr; 38():92-97. PubMed ID: 29287190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.
    Nguyen-Dumont T; Myszka A; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    BMC Med Genet; 2018 Jan; 19(1):12. PubMed ID: 29351780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan.
    Rashid MU; Muhammad N; Khan FA; Hamann U
    Breast Cancer Res Treat; 2015 Jul; 152(1):229-230. PubMed ID: 26067930
    [No Abstract]   [Full Text] [Related]  

  • 9. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.
    Catucci I; Osorio A; Arver B; Neidhardt G; Bogliolo M; Zanardi F; Riboni M; Minardi S; Pujol R; Azzollini J; Peissel B; Manoukian S; De Vecchi G; Casola S; Hauke J; Richters L; Rhiem K; Schmutzler RK; Wallander K; Törngren T; Borg Å; Radice P; Surrallés J; Hahnen E; Ehrencrona H; Kvist A; Benitez J; Peterlongo P
    Genet Med; 2018 Apr; 20(4):452-457. PubMed ID: 28837162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bi-allelic Recessive Loss-of-Function Variants in FANCM Cause Non-obstructive Azoospermia.
    Kasak L; Punab M; Nagirnaja L; Grigorova M; Minajeva A; Lopes AM; Punab AM; Aston KI; Carvalho F; Laasik E; Smith LB; ; Conrad DF; Laan M
    Am J Hum Genet; 2018 Aug; 103(2):200-212. PubMed ID: 30075111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
    García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
    Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants.
    Lim BWX; Li N; Mahale S; McInerny S; Zethoven M; Rowley SM; Huynh J; Wang T; Lee JEA; Friedman M; Devereux L; Scott RJ; Sloan EK; James PA; Campbell IG
    J Natl Cancer Inst; 2023 Feb; 115(2):181-189. PubMed ID: 36315097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing of Finnish hereditary breast cancer families.
    Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
    Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene.
    Silvestri V; Zelli V; Valentini V; Rizzolo P; Navazio AS; Coppa A; Agata S; Oliani C; Barana D; Castrignanò T; Viel A; Russo A; Tibiletti MG; Zanna I; Masala G; Cortesi L; Manoukian S; Azzollini J; Peissel B; Bonanni B; Peterlongo P; Radice P; Palli D; Giannini G; Chillemi G; Montagna M; Ottini L
    Cancer; 2017 Jan; 123(2):210-218. PubMed ID: 27648926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited predisposition to breast cancer among African American women.
    Churpek JE; Walsh T; Zheng Y; Moton Z; Thornton AM; Lee MK; Casadei S; Watts A; Neistadt B; Churpek MM; Huo D; Zvosec C; Liu F; Niu Q; Marquez R; Zhang J; Fackenthal J; King MC; Olopade OI
    Breast Cancer Res Treat; 2015 Jan; 149(1):31-9. PubMed ID: 25428789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.
    Kiiski JI; Fagerholm R; Tervasmäki A; Pelttari LM; Khan S; Jamshidi M; Mantere T; Pylkäs K; Bartek J; Bartkova J; Mannermaa A; Tengström M; Kosma VM; Winqvist R; Kallioniemi A; Aittomäki K; Blomqvist C; Nevanlinna H
    Int J Cancer; 2016 Dec; 139(12):2760-2770. PubMed ID: 27542569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor.
    Peterlongo P; Catucci I; Colombo M; Caleca L; Mucaki E; Bogliolo M; Marin M; Damiola F; Bernard L; Pensotti V; Volorio S; Dall'Olio V; Meindl A; Bartram C; Sutter C; Surowy H; Sornin V; Dondon MG; Eon-Marchais S; Stoppa-Lyonnet D; Andrieu N; Sinilnikova OM; ; Mitchell G; James PA; Thompson E; ; ; Marchetti M; Verzeroli C; Tartari C; Capone GL; Putignano AL; Genuardi M; Medici V; Marchi I; Federico M; Tognazzo S; Matricardi L; Agata S; Dolcetti R; Della Puppa L; Cini G; Gismondi V; Viassolo V; Perfumo C; Mencarelli MA; Baldassarri M; Peissel B; Roversi G; Silvestri V; Rizzolo P; Spina F; Vivanet C; Tibiletti MG; Caligo MA; Gambino G; Tommasi S; Pilato B; Tondini C; Corna C; Bonanni B; Barile M; Osorio A; Benitez J; Balestrino L; Ottini L; Manoukian S; Pierotti MA; Renieri A; Varesco L; Couch FJ; Wang X; Devilee P; Hilbers FS; van Asperen CJ; Viel A; Montagna M; Cortesi L; Diez O; Balmaña J; Hauke J; Schmutzler RK; Papi L; Pujana MA; Lázaro C; Falanga A; Offit K; Vijai J; Campbell I; Burwinkel B; Kvist A; Ehrencrona H; Mazoyer S; Pizzamiglio S; Verderio P; Surralles J; Rogan PK; Radice P
    Hum Mol Genet; 2015 Sep; 24(18):5345-55. PubMed ID: 26130695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.